US Rx spending outlook through 2028: We look back at medication use and spending in 2023 while exploring what will drive spending growth through 2028.
Vitamin Shoppe launches GLP-1 telehealth service: Another legacy retailer is throwing its hat in the GLP-1 ring. Here’s why the promise of low cost GLP-1s isn’t always what it seems.
Hims & Hers’ stock price flips after topsy-turvy week: CEO Andrew Dudum’s controversial comments on Gaza came days before the company’s record-level subscriber growth. Is this a lesson learned for brands and marketers?
Ro’s new approach to integrated virtual care: Market factors like low telehealth usage are driving some virtual care players to differentiate, and others out of the market entirely.
FDA OKs Apple Watch’s aFib history for clinical studies: The Watch becomes the first digital health tool to be qualified under the FDA’s Medical Device Development Tools program. Here’s what it means for Apple’s health ambitions.
Patients’ health journeys begin online: Here’s what healthcare and pharma marketers need to know about how online-acquired information influences patient action.
FTC challenges drug patents: The Commission argues “junk” patent listings stifle competition and keep drug prices high. We explore what consumers stand to gain via the FTC’s challenge—and its likelihood of success.
Moderna prepping for RSV vaccine launch this fall: We explore how, if approved, the vaccine could open up a new market for the company—and the competitive edge its shot could hold in the entrenched RSV space.
Gen Zers and millennials are embracing healthier habits: They want to invest in both their short- and long-term health. Here’s how health and wellness brands and marketers can seize the opportunity.
Pfizer developing direct-to-consumer platform: We unpack the move and explore why Pfizer won’t be the last pharma player to provide patients with easier access to its medications.
CVS’ Medicare Advantage business is taking some hits: Aetna’s senior members are getting a lot of care, which is driving up costs. Their insurance benefits are likely going to be scaled back as a result.
Optum discontinues its in-house telehealth business: We explore three reasons that could have driven Optum’s decision.
Marketing payments to docs drove Rx volume: But pharma marketers will need to do more than just pay for physicians’ meals to build long-lasting relationships.
Walmart shuts down Walmart Health, Virtual Care businesses: We unpack how common pitfalls faced by other providers plagued Walmart Health—and what the future could hold for the retail health space.
Moderna, OpenAI make genAI pact: Pharma execs have taken a mostly cautious approach with AI. But new market pressures will drive more accelerated adoption of the tech.
US drug spending is on the rise: The 13.5% increase in 2023 was largely driven by weight loss meds. We explore the broader implications for US healthcare—and how and when this spending should be addressed.
Nurses protest AI in healthcare: Concerns center on a perceived rush to implement untested, unregulated tech. This piles on nurses’ laundry list of issues with their employers—the pressure is mounting on hospitals to respond.
What the FTC’s noncompete ban means for healthcare providers: 40% of physicians are bound by noncompetes. While it might take a while to enforce, it could shift power from employers back to doctors.
Walgreens expands specialty pharmacy services: It’s pulling back on primary care while getting deeper into specialty pharmacy. Can it catch up to CVS, Cigna, and United?
TikTok pulls out the stopwatch on GLP-1 content: It’s restricting most content related to weight loss drugs. We explore what this means for health influencers and the pharma marketers who sponsor them.